Servier

News

Servier wagers $2.65bn on Edgewise muscular dystrophy drug

Servier has signed the largest licensing deal in its history, paying $1.55bn upfront for Edgewise's muscular dystrophy business headed by sevasemten.

News

IDEAYA/Servier PKC drug aces uveal melanoma trial

Servier $210m bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.

Oncology

Day One's big bet on tovorafenib just keeps paying off

Now set to be acquired by Servier for $2.5 billion, Day One Bio proves how far a mission-driven biotech with a strong team and good timing can go.

News

Servier snaps up cancer biotech Day One in $2.5bn deal

Servier has made a takeover offer for Day One and its fast-growing glioma therapy Ojemda, as it pitches to drive sales above €10bn by 2030.

Digital

pharmaphorum podcast Episode 242, Yann Gaston-Mathe, Iktos

JPM2026: Broadening AI drug discovery to include the lab, wi...

Yann Gaston-Mathe, founder and CEO of Iktos, discusses AI drug discovery's shift to real-world operations that are able to incorporate wet lab data.

News

Now Iktos teams up with Pierre Fabre in oncology

As Servier announces its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has revealed an integrated collaboration with Iktos

Servier wagers $2.65bn on Edgewise muscular dystrophy drug

IDEAYA/Servier PKC drug aces uveal melanoma trial

Day One's big bet on tovorafenib just keeps paying off

Servier snaps up cancer biotech Day One in $2.5bn deal

JPM2026: Broadening AI drug discovery to include the lab, wi...

Now Iktos teams up with Pierre Fabre in oncology

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

Discover a new era of healthcare panel engagement: Grounded ...

Servier

Editor's Picks